Alpine Immune Sciences, Inc. (ALPN): Price and Financial Metrics
ALPN Price/Volume Stats
| Current price | $64.60 | 52-week high | $64.72 |
| Prev. close | $64.60 | 52-week low | $6.71 |
| Day low | $64.58 | Volume | 2,816,700 |
| Day high | $64.68 | Avg. volume | 1,931,467 |
| 50-day MA | $46.10 | Dividend yield | N/A |
| 200-day MA | $23.39 | Market Cap | 4.24B |
ALPN Stock Price Chart Interactive Chart >
Alpine Immune Sciences, Inc. (ALPN) Company Bio
Alpine Immune Sciences, Inc. is focused on developing novel protein‐based immunotherapies using its proprietary Variant Ig Domain vIgD platform technology. The vIgD platform is designed to interact with multiple targets, including many present in the immune synapse. Alpine’s vIgDs are developed using a process known as directed evolution, which can potentially produce proteins capable of either enhancing or diminishing an immune response and thereby may potentially apply therapeutically to both oncology and inflammatory diseases. The company formed following a July, 2017 merger with Nivalis Therapeutics.
Latest ALPN News From Around the Web
Below are the latest news stories about ALPINE IMMUNE SCIENCES INC that investors may wish to consider to help them evaluate ALPN as an investment opportunity.
Alpine Immune Sciences Announces Amendment of Acazicolcept Option and License Agreement with AbbVieSEATTLE, December 21, 2023--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced today that the Company has amended the previously announced 2020 option and license agreement with AbbVie for acazicolcept. |
Is Alpine Immune Sciences (ALPN) Stock Outpacing Its Medical Peers This Year?Here is how Alpine Immune Sciences, Inc. (ALPN) and Corbus Pharmaceuticals (CRBP) have performed compared to their sector so far this year. |
Alpine Immune Sciences to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceSEATTLE, December 18, 2023--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that Mitchell Gold, M.D., Executive Chairman and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 7:30 am PT/10:30 am ET, and the Company will participate in one-on-one investor meetings. |
Optimistic Investors Push Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Shares Up 41% But Growth Is LackingDespite an already strong run, Alpine Immune Sciences, Inc. ( NASDAQ:ALPN ) shares have been powering on, with a gain... |
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey MedicalAurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey Medical are part of the Zacks Industry Outlook article. |
ALPN Price Returns
| 1-mo | 69.51% |
| 3-mo | 133.30% |
| 6-mo | 301.99% |
| 1-year | 844.44% |
| 3-year | 456.42% |
| 5-year | 935.26% |
| YTD | 238.93% |
| 2023 | 159.32% |
| 2022 | -46.93% |
| 2021 | 9.92% |
| 2020 | 228.13% |
| 2019 | 4.35% |
Continue Researching ALPN
Want to do more research on Alpine Immune Sciences Inc's stock and its price? Try the links below:Alpine Immune Sciences Inc (ALPN) Stock Price | Nasdaq
Alpine Immune Sciences Inc (ALPN) Stock Quote, History and News - Yahoo Finance
Alpine Immune Sciences Inc (ALPN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...